Cue Biopharma (CUE) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cue Biopharma (CUE) has outperformed Veraxa Biotech (VRXA) over the past year, losing 0.2% versus a loss of 88.5%. Veraxa Biotech is the larger company by market cap ($169.7 million vs $163.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | VRXA |
|---|---|---|
| Share price | $22.51 | $1.20 |
| Market cap | $163.52M | $169.69M |
| 1-day change | -2.72% | +11.11% |
| YTD return | +146.01% | -88.75% |
| 1-year return | -0.22% | -88.53% |
| 5-year return | -94.04% | — |
| EPS (TTM) | $-28.75 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $27.36 |
| 52-week low | $4.98 | $1.04 |
| Distance from 52-week high | -50.53% | -95.61% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +290.94% | — |
| Average volume | 269.82K | 267.22K |
| Shares outstanding | 7.26M | 141.41M |
| Employees | 29 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed VRXA by 88.3 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Healthcare · Biotechnology · 29 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Healthcare · Biotechnology
CUE vs VRXA FAQ
Which is bigger, Cue Biopharma or Veraxa Biotech?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $169.69M compared with $163.52M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or VRXA?
CUE returned -0.22% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.